Note: Each top story has links to more detailed information. A nice recap of AASLD's Liver Meeting. AF
Healio.com/Hepatology has compiled a list of the latest, most relevant research on hepatitis C virus infection, presented recently at The Liver Meeting 2015 in San Francisco.
Medicaid patients with HCV more often denied DAA therapy
“The implications of these denials of DAA therapy remain unclear. But, it certainly may be that they have downstream adverse outcomes for both patients and providers,” Vincent Lo Re, MD, MSCE, said during his presentation. Read more
ASTRAL-2: Sovaldi/velpatasvir bests standard therapy in HCV genotype 2
A fixed-dose combination of Sovaldi and velpatasvir yielded better sustained virologic response rates in patients with genotype 2 hepatitis C virus than Sovaldi and ribavirin, the current standard of care.
Labels: AASLD 2015 Liver Meeting